ReviewJournal of neuroscience research2017
Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.
Review in Journal of neuroscience research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis.International journal of medical sciences · 2020Pooled it
- Loss of ADAP1/CentA1 Protects Against Autoimmune Demyelination.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Macrophage polarization: an important role in inflammatory diseases.Frontiers in immunology · 2024Review
- Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- 1,25(OH)International journal of molecular sciences · 2023Article
- Multi-omics analysis of magnetically levitated plasma biomolecules.Biosensors & bioelectronics · 2023Article
- Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?Neural regeneration research · 2022Review
- Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges.Cellular and molecular life sciences : CMLS · 2022Review
- miR-20a suppresses Treg differentiation by targeting Map3k9 in experimental autoimmune encephalomyelitis.Journal of translational medicine · 2021Article
- PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective.Frontiers in cellular neuroscience · 2021Review
- Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner.Inflammopharmacology · 2020Article
- Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.Multiple sclerosis and related disorders · 2020Article
- Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases.Journal of translational medicine · 2020Review
- ADAMTS13 ameliorates inflammatory responses in experimental autoimmune encephalomyelitis.Journal of neuroinflammation · 2020Article
- RNAi-mediated knockdown of VDR surprisingly suppresses cell growth in Jurkat T and U87-MG cells.Heliyon · 2019Article
- Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions.Journal of neuropathology and experimental neurology · 2019Article
- Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis.Frontiers in pharmacology · 2019Review
- When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.Assay and drug development technologies · 2017Article
- Peripherally Induced Regulatory T Cells: Recruited Protectors of the Central Nervous System against Autoimmune Neuroinflammation.Frontiers in immunology · 2017Review
- Anemoside A3 ameliorates experimental autoimmune encephalomyelitis by modulating T helper 17 cell response.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system with an autoimmune attack on the components of the myelin sheath and axons. The etiology of the disease remains largely unknown, but it is commonly acknowledged that the development of MS probably results from the interaction of environmental factors in conjunction with a genetic predisposition. Current therapeutic approaches can only ameliorate the clinical symptoms or reduce the frequency of relapse in MS. Most drugs used in this disease broadly suppress the functions of immune effector cells, which can result in serious side effects. Thus, new therapeutic methods resulting in greater efficacy and lower toxicity are needed. Toward this end, cell-based therapies are of increasing interest in the treatment of MS. Several immunoregulatory cell types, including regulatory T cells, regulatory B cells, M2 macrophages, tolerogenic dendritic cells, and stem cells, have been developed as novel therapeutic tools for the treatment of MS. In this Review, we summarize studies on the application of these cell populations for the treatment of MS and its animal model, experimental autoimmune encephalomyelitis, and call for further research on applications and mechanisms by which these cells act in the treatment of MS. © 2017 The Authors Journal of Neuroscience Research Published by Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.